- NanoVibronix (NAOV, Financial) has successfully regained full compliance with Nasdaq listing requirements.
- The company has met the $1.00 minimum bid price and $2.5 million stockholders' equity requirements.
- Despite compliance, NanoVibronix will remain under a Mandatory Panel Monitor until April 9, 2026.
On April 9, 2025, NanoVibronix, Inc. (NASDAQ: NAOV), a medical technology firm specializing in non-invasive therapeutic devices, announced that it has regained full compliance with Nasdaq listing requirements. The company received formal notification confirming that it now meets all the necessary criteria, including the critical $1.00 minimum bid price and $2.5 million stockholders' equity requirements.
Despite resolving the previously disclosed listing concern and regaining its status on The Nasdaq Capital Market, NanoVibronix will remain under a Mandatory Panel Monitor until April 9, 2026, according to Nasdaq's Listing Rule 5815(d)(4)(B).
NanoVibronix, headquartered in Tyler, Texas, focuses on developing medical devices using its patented low intensity surface acoustic wave (SAW) technology. The company’s products, such as PainShield® and UroShield®, offer non-invasive treatment options that can be administered at home or in various care settings. These devices primarily help in pain relief and the disruption of biofilms and bacterial colonization.
The company's successful compliance with Nasdaq's requirements ensures continued trading on a major exchange, providing better market visibility for shareholders. For more information, you can visit their official website at NanoVibronix.
